Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells

Molecular Pharmacology

Volumn 50, Issue 6, 1996, Pages 1502-1510

  Cihlar, Tomas ^a,b   Chen, Ming S ^a  

^a Dept Biochem Virol Gilead Sci ^*  (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; PHOSPHOGLYCERATE MUTASE; PYRIMIDINE NUCLEOSIDE;

ARTICLE; CATALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; HOST CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTIVIRAL AGENTS; CATALYSIS; CELL LINE; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; HUMANS; KINETICS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PHOSPHORYLATION; PHOSPHOTRANSFERASES;

EID: 0030480275     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. De Clercq, E. Broad spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. Biochem. Pharmacol. 42:963-972 (1991).
2. De Clercq, E. Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Virol. 3:85-96 (1993).
3. Lalezari, J. P., W. L. Drew, E. Glutzer, C. James, D. Miner, J. Flaherty, P. E. Fisher, K. C. Cundy, J. Hannigan, J. C. Martin, and H. S. Jaffe. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (cidofovir): results of the phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171:788-796 (1995).
4. Lalezari, J., H. S. Jaffe, T. Schacker, J. Feinberg, S. Lee, J. Gathe, F. Kramer, H. Kessler, T. Cheung, B. McGuire, and S. Safrin. A randomized double-blinded, placebo-controlled study of cidofovir topical gel for acyclovir-resistant herpes-simplex virus infection in patients with AIDS, in The 3rd Conference on Retroviruses and Opportunistic Infections. Infectious Diseases Society of America, Alexandria, VA, A174 (1996).
5. Cihlar, T., I. Votruba, K. Horska, R. Liboska, I. Rosenberg, and A. Holy. Metabolism of 1-(S)-(3-hydroxy-2-phosphonomethoxypropyl)cytosine (HPMPC) in human embryonic lung cells. Collect. Czech. Chem. Commun. 57:661-672 (1992).
6. Ho, H.-T., K. L. Woods, J. J. Bronson, H. De Boeck, J. C. Martin, and M. J. M. Hitchcock. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine. Mol. Pharmacol. 41:197-202 (1992).
7. Xiong, X., J. Smith, C. Kim, E.-S. Huang, and M. S. Chen. Kinetic analysis of the interaction of cidofovir with human cytomegalovirus DNA polymerase. Biochem. Pharmacol. 51:1563-1567 (1996).
8. Miller, W. H., and R. L. Miller. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem. Pharmacol. 31:3879-3884 (1982).
9. Mendel, D. B., D. B. Barkhimer, and M. S. Chen. Biochemical basis of increased susceptibility to cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Antimicrob. Agents Chemother. 39:2120-2122 (1995).
10. Cherington, J. M., R. Miner, M. J. M. Hitchcock, J. P. Lalezari, and W. L. Drew. Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various clinical regimens of drug. J. Infect. Dis. 173:987-992 (1996).
11. Merta, A., I. Votruba, J. Jindrich, A. Holy, T. Cihlar, I. Rosenberg, M. Otmar, and T. Y. Herve. Phosphorylation of 9-(2- phosphonomethoxyethy-1)adenine by AMP(dAMP) kinase from L1210. Biochem. Pharmacol. 44: 2067-2077 (1992).
12. Balzarini, J., J.-F. Nave, M. A. Becker, M. Tatibana, and E. De Clercq. Kinetic properties of adenine nucleotide analogues against purified 5-phosphoribosyl-1-pyrophosphate synthetases from E. coli, rat liver and human erythrocytes. Nucleosides Nucleotides 14:1861-1871 (1995).
13. Terry, B. J., K. E. Mazina, A. V. Tuomari, M. L. Haffey, M. Hagen, A. Feldman, W. A. Slusarchyk, M. G. Young, R. Zahler, and A. K. Field. Broad spectrum antiviral activity of the acyclic guanosine phosphonate (R,S)-HPMPG. Antiviral Res. 10:235-251 (1988).
14. 2 isoenzyme of pyruvate kinase from human kidney as a product of a separate gene: its purification and characterization. Biochemistry 16:3831-3837 (1977).
15. Hall, E. R., and G. L. Cottam. Isozymes of pyruvate kinase in vertebrates: their physical, chemical, kinetic and immunological properties. Int. J. Biochem. 9:785-793 (1978).
16. Cleland, W. W. Statistical analysis of enzyme kinetic data. Methods Enzymol. 63:103-138 (1979).
17. Bischofberger, N., M. J. M. Hitchcock, M. S. Chen, D. B. Barkhimer, K. C. Cundy, K. M. Kent, S. A. Lacy, W. A. Lee, Z.-H. Li, D. B. Mendel, D. F. Smee, and J. L. Smith. 1-[((S)-2-Hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vitro. Antimicrob. Agents Chemother. 38:2387-2391 (1994).
18. Hande, K. R., and B. A. Chabner. Pyrimidine nucleoside monophosphate kinase from human leukemic blast cells. Cancer Res. 38:579-585 (1978).
19. Seagrave, J., and P. Reyes. Pyrimidine nucleoside monophosphate kinase from rat bone marrow cells: purification to high specific activity by a two-step affinity chromatography procedure. Anal. Biochem. 149:169-176 (1985).
20. Scott, E. M., and R. C. Wright. Kinetics and equilibria of pyrimidine nucleoside monophosphate kinase from human erythrocytes. Biochim. Biophys. Acta 571:45-54 (1979).
21. Parks, R. E., and R. P. Agarwal. Nucleotide diphosphate kinases, in The Enzymes (P. D. Boyer, ed.). 3rd ed. Academic Press, New York, 307-334 (1973).
22. Plowman, K. M., and A. R. Krall. A kinetic study of nucleotide interaction with pyruvate kinase. Biochemistry 4:2809-2814 (1965).
23. James, E., and J. F. Morrison. The reaction of nucleotide substrate analogues with adenosine triphosphate-creatine phosphotransferase. J. Biol. Chem. 241:4758-4766 (1966).
24. Mourad, N., and R. E. Parks, Jr. Erythrocytic nucleoside diphosphokinase. I. Isolation and kinetics. J. Biol. Chem. 241:271-278 (1966).
25. Kimura, N., and N. Shimada. Membrane-associated nucleoside diphosphate kinase from rat liver. J. Biol. Chem. 263:4647-4653 (1988).
26. Walliman, T., M. Wyss, D. Brdiczka, K. Nicolay, and H. M. Eppenberger. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the "phosphocreatine circuit" for cellular energy homeostasis. Biochem. J. 281:21-40 (1992).
27. Kayne, F. J. Pyruvate kinase, in The Enzymes (P. D. Boyer, ed.). 3rd ed. Academic Press, New York, 353-383 (1973).
28. Scopes, R. K. 3-Phosphoglycerate kinase, in The Enzymes (P. D. Boyer, ed.). 3rd ed. Academic Press, New York, 335-352 (1973).
29. Bridger, W. A. Succinyl-CoA synthetase, in The Enzymes (P. D. Boyer, ed.). 3rd ed. Academic Press, New York, 581-606 (1974).
30. Bais, R., and J. B. Edwards. Creatine kinase. CRC Crit. Rev. Clin. Lab. Sci. 16:291-333 (1982).
31. Colberg-Poley, A. M., and L. D. Santomenna. Selective induction of chromosomal gene expression by human cytomegalovirus. Virology 166:217-228 (1988).
32. Colberg-Poley, A. M., L. D. Santomenna, P. P. Harlow, P. A. Benfield, and D. J. Tenney. Human cytomegalovirus US3 and UL36-38 immediate early proteins regulate gene expression. J. Virol. 66:95-105 (1992).
33. Boldogh, I., E. Gonczol, L. Gartner, and L. Vaczi. Stimulation of host DNA synthesis and induction of early antigens by ultraviolet light irradiated human cytomegalovirus. Arch. Virol. 58:289-299 (1978).
34. Boldogh, I., S. AbuBakar, M. P. Fons, C. Z. Deng, and T. Albrecht. Activation of cellular oncogenes by clinical isolates and laboratory strains of human cytomegalovirus. J. Med. Virol. 34:241-247 (1991).
35. Muganda, P., O. Mendoza, J. Hernandez, and Q. Qian. Human cytomegalovirus elevates levels of protein p53 in infected fibroblasts. J. Virol. 68:8028-8034 (1994).
36. Caswell, R. C., C. Hagemeier, G. P. Hayhurst, T. Kouzarides, and J. H. Sinclair. Mechanism of transactivation of cellular promoters by the HCMV major immediate early proteins involve direct interaction with cellular transcription factors, in Multidisciplinary Approach to Understanding Cytomegalovirus Diseases (S. Michelson and S. A. Plotkin, eds.). Elsevier Science Publishers, Amsterdam, 13-16 (1993).
37. Chee, M. S., A. T. Bankier, S. Beck, R. Bohni, C. M. Brown, R. Cerny, T. Horsnell, C. A. Hutchinson III, T. Kouzarides, J. A. Martignetti, E. Preddie, S. C. Satchwell. P. Tomplinson, K. M. Weston, and P. G. Barrell. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD 169. Curr. Topics Microbiol. Immunol. 154:125-169 (1990).
38. Landini, M. P. Early enhanced glucose uptake in human cytomegalovirus-infected cells. J. Gen. Virol. 65:1229-1232 (1984).
39. Wachsman, M., F. M. Hamzeh, H. Saito, and P. S. Leitman. Anticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cells. Antimicrob. Agents Chemother. 40:433-436 (1996).
40. Connelly, M. C., B. L. Robbing, and A. Fridland. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonomethoxyethyl)-cytosine (HPMPC) in Vero cells. Biochem. Pharmacol. 46:1053-1057 (1993).
41. Keim, D., N. Hailat, R. Melhem, X. X. Zhu, I. Lascu, M. Veron, R. Strahler, and S. M. Hanash. Proliferation-related expression of p19/nm23 nucleoside diphosphate kinase. J. Clin. Invest. 89:919-924 (1992).